Finally, we can all get that green monkey off our backs. Some researchers at Yale published a study Thursday about their clinical trial of an experimental new drug to treat the horrors of cannabis withdrawal.
The paper was published in the psychological journal Lancet under the catchy title: “Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.”
It’s authors, it should be noted, have great names worthy of the members of a ‘60s psychedelic band, including Grai Bluez (for real), Gina Creatura, Emma Deaso, Jose Cortes-Briones, and, on lead didgeridoo and vocals, Prof. Deepak Cyril D’Souza.
Basically, their study posits that when a stoner quits weed cold turkey, they will experience withdrawal symptoms. Though the study doesn’t actually list those symptoms, the study’s financial sponsor, the U.S. National Institute on Drug Abuse (NIDA), does: “irritability, mood and sleep difficulties, decreased appetite, cravings, restlessness, and/or various forms of physical discomfort that peak within the first week after quitting and last up to 2 weeks.”
But for those who can’t ride out the restlessness for up to two weeks, there may soon be a drug on the market to make getting off the weed as easy as quitting coffee or sugar (oh wait, those are actually more addictive than cannabis).
According to the report by D’Souza and company, their treatment showed some successful in reducing the withdrawal symptoms of test subjects. In particular, subjects taking the drug got significantly better sleep than those taking the placebo.
The test was given to a relatively small sample size (70 men, no women), but The Independent reports that they’re now embarking on a much larger clinical trial.
If the drug
Photo via Flickr user Heath Alseike